Journal article
Collaterals at angiography and outcomes in the interventional management of stroke (IMS) III trial
DS Liebeskind, TA Tomsick, LD Foster, SD Yeatts, J Carrozzella, AM Demchuk, TG Jovin, P Khatri, R Von Kummer, RM Sugg, OO Zaidat, SI Hussain, M Goyal, BK Menon, F Al Ali, B Yan, YY Palesch, JP Broderick
Stroke | Published : 2014
Abstract
Background and Purpose-Endovascular strategies provide unique opportunity to correlate angiographic measures of collateral circulation at the time of endovascular therapy. We conducted systematic analyses of collaterals at conventional angiography on recanalization, reperfusion, and clinical outcomes in the endovascular treatment arm of the Interventional Management of Stroke (IMS) III trial. Methods-Prospective evaluation of angiographic collaterals was conducted via central review of subjects treated with endovascular therapy in IMS III (n=331). Collateral grade before endovascular therapy was assessed with the American Society of Interventional and Therapeutic Neuroradiology/Society of In..
View full abstractGrants
Awarded by National Institute of Neurological Disorders and Stroke
Funding Acknowledgements
This work has been funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) awards P50NS044378, K24NS072272, R01NS077706, and R13NS082049. IMS III funding included NIH/NINDS awards U01NS052220, U01NS054630, and U01NS077304. Genentech Inc supplied the study drug for intra-arterial t-PA in the endovascular group. EKOS Corp, Concentric Inc, and Cordis Neurovascular Inc supplied study catheters during Amendments 1 to 3. In Europe, IMS III investigator meeting support was provided in part by Boehringer Ingelheim.